natgillin/translations-raw huggingface dataset:
The conjugate may also be mixed with further antigens. In one embodiment the further antigens comprise at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 S. pneumoniae saccharides selected from the group consisting of 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1-7, naznačen time što uključuje dodatni korak miješanja konjugata s dodatnim antigenima, gdje dodatni antigeni mogu sadržavati najmanje 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 ili 20 saharida iz bakterije S. pneumoniae, koje se bira iz skupine koju čine 1, 2, 3, 4, 5, GA, 6B, TF, 8, JN, JV, 10A, ITA, 12F, 14, 15B, 1I7F, 18C, 19A, 19F, 20, 22F, 23F 1 33F.
The compound of claim 1, wherein the compound is: 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što spoj ima formulu:
This glassy off white solid was scraped out and further dried at 0.15 Torr at 25°C for 24 hr to yield 17.3 g of desired C-arylglucoside containing 6.7 mol% of EtOAc. 
Ova staklasta HR P20090113 T3 prljavo bijela čvrsta supstanca je ostrugana i dalje sušena na 0.15 Torr i na 25*C 24 sata, te se proizvelo 17.3 g željenog C-arilglukozida koji sadrži 6.7 mol% EtOAc.
For column sanitization, the column was flushed with at least 1 BV of NaOH 0.5 M, then rinsed with 3-5 BV of purified water. 
Za sterilizaciju kolone, ista je bila oprana s najmanje 1 BV 0.5M NaOH, a onda još jednom s 3-5 BV pročišćene vode.
A pharmaceutical composition comprising at least two immunoconjugates of claim 6, wherein the immunoconjugates have an average of about 3 to about 4 (C) per (A). A diagnostic reagent comprising the antibody or antigen binding fragment thereof of claim 1 . 
Farmaceutska kompozicija koja sadrži imunokonjugat iz bilo kojeg od patentnih zahtjeva 7-15, gdje imunokonjugat ima prosjek od oko 3 do oko 4 (C) po (A) ili prosjek od oko 3.5 (C) po (A).
The pharmaceutical composition according to claim 1, wherein said pharmaceutical composition is administered orally, parenterally, intramuscularly or topically. The pharmaceutical composition according to claim 1, wherein said pharmaceutical composition is in the form of a tablet, capsule, sachet, injectable preparation, suspension, syrup, gel, cream or ointment. 
Farmaceutski pripravak prema bilo kojem od prethodnih zahtjeva, naznačen time što je navedeni farmaceutski pripravak pogodan za oralnu, parenteralnu, intramuskularnu ili topičku administraciju, te kao takav dolazi u obliku tablete, kapsule, kao prah u vrećici, injektibilnog preparata, suspenzije, sirupa, gela, kreme, pomade.
The compound of any one of claims 1-3 wherein at least one of E1a and E1b is -N(H)(cycloalkylcarbonyl) or -N(H)(cycloalkyloxycarbonyl). 
Spoj iz bilo kojeg od patentnih zahtjeva 1-3 gdje najmanje jedno od E'* i E" je -N(H)(cikloalkilkarbonil) ili - N(H)(cikloalkiloksikarbonil).
The compound of claim 1, wherein R1-R2 is 
Spoj sukladno patentnom zahtjevu 1, naznačeno time R1-R2 da je H
Both the amorphous and the crystallized pellets had a silicon content of 222 ug/g of pellets. 
I amorfne i kristalizirane pelete imaju sadržaj silikona od 222 ug/g peleta.
The solid oral extended release pharmaceutical dosage form of claim 1, wherein the density of the extended release matrix formulation is equal to or less than about 1.20 g/cm3 preferably equal to or less than about 1.19 g/cm3. 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema bilo kojem od zahtjeva 1 do 13, naznačen time da je gustoća formulacije matrice sa produljenim otpuštanjem jednaka ili manja od oko 1.20 g/cm3, poželjno jednaka ili manja od oko 1.19 g/cm3.
The compound for use of claim 8, wherein the leukemia is chronic lymphocytic leukemia, chronic myelocytic leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia or acute myeloblastic leukemia. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 11, naznačen time što je leukemija kronična limfocitna leukemija, kronična mijelocitna leukemija, akutna limfoblastična leukemija, akutna mijelogena leukemija ili akutna mijeloblastična leukemija.
The pharmaceutical composition of claim 1 for use in the treatment of acute decompensated heart failure. The pharmaceutical composition of claim 14 for use in the treatment of heart failure. 
Spoj patentnog zahtjeva 1 ili patentnog zahtjeva 2 ili farmaceutska kompozicija bilo kojeg od patentnih zahtjeva 3-7 za primjenu u liječenju srčane insuficijencije.
the vertical arm 111 comprises a box-shaped accommodation 112, which is open both on the front side, i.e. 
- < okomiti krak 111 čine kutijasti uređaj 112, otvoren i sprijeda, tj.
The process of any preceding claim, further comprising a step in which the vaccine and/or the culture is tested for the presence of a pathogen selected from the group consisting of parainfluenza viruses; Herpesviridae; Mycoplasma; and avian circoviruses. 
HR P20130962 T1 PATENTNI ZAHTJEVI Postupak priprave antigena cjepiva u kulturi Vero stanične linije, koji sadrži korak testiranja na patogen izabran iz skupine koja sadrži parvovirus, JC poliomavirus 1 cirkovirus.
The use of claim 16, for the manufacture of a medicament for the treatment of cancer selected from the group consisting of tumors of the central nervous system, head and neck cancer, lung cancer, such as NSCLC, breast cancer, specifically triple negative breast cancer, esophageal cancer, gastric or stomach cancer, liver and biliary cancer, pancreatic cancer, colorectal cancer, bladder cancer, kidney cancer, prostate cancer, endometrial cancer, ovarian cancer, malignant melanoma, sarcoma, tumors of unknown primary origin, bone marrow cancer, acute lymphoblastic leukemia, AML, chronic lymphoblastic leukemia and non-Hodgkin lymphoma, skin cancer, glioma, cancer of the brain, uterus, and rectum. 
Uporaba prema zahtjevu 16, naznačena time, da je za proizvodnju lijeka za liječenje raka odabranog iz skupine koju čine tumori centralnog nervnog sustava, rak glave 1 vrata, rak pluća, kao što je primjerice NSCLC, rak dojke, osobito trostruko negativan rak dojke, rak jednjaka, gastrički Tak ili rak želudca, rak jetre 1 žuči, rak pankreasa, kolorektalni rak, rak mjehura, rak bubrega, rak prostate, rak endometrija, rak jajnika, maligni melanom, sarkom, tumori nepoznatog primarnog podrijetla, rak koštane srži, akutna limfoblastna leukemija, AML, kronična limfoblastna leukemija i ne-Hodgkin-limfom, rak kože, gliom, rak mozga, uterusa i rektuma.
during a startup mode directing at least a part of the dewatered sludge through a heat exchanger bypass line and to the hydrolysis reactor; and 
(i) tijekom pokretanja rada usmjeravanjem barem dijela odvodnjenog mulja kroz obilazni vod (25) izmjenjivača topline i u reaktor za hidrolizu (214); 1
A solution as claimed in claim 1, wherein the solution comprises N x (0.3 to 1.4) g/L of preservative. 
Otopina u skladu s patentnim zahtjevom 1, naznačena time što otopina sadrži N x (0,3 do 1.4) g/l konzervansa.
The anti-RSV immune response inducing composition of claim 7, for use in a method wherein administering in (a) is during the second or third trimester of pregnancy. 
Pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 2, naznačen time što se pripravak koji izaziva imunosni odgovor protiv RSV kojeg se primjenjuje na navedenoj ženi primjenjuje tijekom drugog ili trećeg tromjesečja trudnoće.
The other LED illuminates when the available battery power falls below a predetermined level, and is a signal to the user to replace the batteries. 
Druga LED dioda svijetli kad raspoloživa snaga baterije pada ispod određene razine, te služi kao signal korisniku da zamijeni baterije.
The method of claim 1, wherein administration of the composition maintains the level of functional C1 esterase inhibitor in the blood of the subject at or above 0.4 U/mL for at least 50% of the time between administrations. The method of claim 1, wherein administration of the composition maintains the level of functional C1 esterase inhibitor in the blood of the subject at or above 0.4 U/mL for at least 75% of the time between administrations. 
Pripravak za uporabu prema bilo kojem prethodnom zahtjevu, naznačen time što davanje najmanje jednog inhibitora C1 esteraze dovodi do povećanih razina inhibitora C1 esteraze u krvi subjekta, pri čemu su razine inhibitora C1 esteraze u krvi povećane do najmanje 0,3 U/mL, 0,4 U/mL, ili do 1 U/mL.
Stirring continues for a further 2 hours after which time, the reaction mixture is partitioned between ethyl acetate/diethyl ether (80 ml of a 1:1 mixture) and water (100 ml). 
Miješanje se nastavi daljnja 2 sata, nakon čega se reakcijsku smjesu podijeli između etil acetata i dietil etera (80 ml 1:1 mješavine) i vode (100 ml).
The compound or salt of any one of Embodiments 34-36, wherein the compound corresponds in structure to Formula (I-b): 
Spoj ili sol prema zahtjevu 14, naznačen time, da spoj ima strukturu koja odgovara Formuli (I-b): 25
In one aspect —X—Y— together represents a group of the formula: wherein: ring A is linked to the pyridine group and —[C(R13)(R14)]s— is linked to the carboxy group; and A is a 4-7 membered mono-, bi- or spiro heterocyclic ring system containing a ring nitrogen atom by which it is attached to the pyridine ring and additionally optionally one other ring heteroatom selected from nitrogen, oxygen and sulphur; 
Spoj prema bilo kojem od zahtjeva 1 to 7 naznačen time da zajedno predstavljaju skupinu formule: (R'%), [C(R'13XR!'4)],- pri čemu: prsten A je vezan na piridinsku skupinu i je vezan na karboksilnu skupinu; i
The pharmaceutical composition of claim 1 which contains in addition a directly compressible polyhydric alcohol. 
Farmaceutski sastav prema zahtjevu 1, naznačen time, da on dodatno sadrži direktno stlačivi polivalentan alkohol.
or a pharmaceutically acceptabl salt thereof comprising the steps of reducing a compound of formula II or an acid addition salt thereof wherein X is defined as above, to obtain a compound of formula I or a pharmaceutically acceptable salt thereof, and 
OH gdje je X definiran kao gore, da bi se dobio spoj formule [ili njegova farmaceutski prihvatljiva sol, te b) po izboru, izolacije spoja formule I ili njegove farmaceutski prihvatljive soli koji su dobiveni u koraku a).
The system according to any preceding claim, wherein the deposit comprises a polymer matrix core. The system according to claim 10, wherein the polymer matrix core comprises an EVA polymer comprising more than 10% vinyl acetate and the deposit has a diameter of from 1.5 to 3.0 mm and a length from 20 to 45 mm. 
Sustav, u skladu sa bilo kojim od prethodnih zahtjeva, naznačen time što se jezgra od polimernog materijala sastoji od EVA polimera, koji sadrži više od 10 % vinil acetata i što je dijametar umetka od 1.0 mm do 3.0 mm, poželjno od 1.5 mm do 3.00 mm i da je dužina od 20 mm do 45 mm, poželjno oko 30 mm.
The method of any one of claims 1 to 7, wherein the protein of interest is an antibody. 
Metoda iz bilo kojeg od prethodnih patentnih zahtjeva, gdje protein je antitijelo.
A nucleic acid comprising a nucleotide sequence encoding any of the polypeptides of any one of claims 1 to 6. 
14. Sastav iz bilo kojeg od patentnih zahtjeva 1 do 13, nadalje sadrži dodatni antigen.
The herbicidal mixtures or compositions according to the invention are very suitable for fighting or controlling a broad spectrum of grasses and broadleaf weeds which are accompanying in general the abovementioned crops, e.g. in particular brassica napus (oil seed rape, canola). Very preferably the weeds in ALS-herbicide resistant or tolerant brassica napus (oilseed rape, canola) are fighted by the herbicidal mixtures or compositions according to the invention. 
Herbicidne smjese ili kompozicije prema izumu, na primjer smjese koje sadrže imazamoks 1 kloroacetamid (na primjer one kao što su navedene pod MI, M 1-1, M 1-2, M2, M2-1, M3, M3-1, M4, M4-1, M5 i M5-1) su vrlo pogodne za suzbijanje ili za kontrolu širokog spektra trava i širokolisnih korova koji prate općenito gore navedene kulture, npr., posebno Brassica napus (uljana repica, kanola).
In a preferred embodiment, following the purification step, the purified cells are further expanded via in-vitro treatment with MCSF at a concentration of about 35-55 nM, preferably about 50 nM, more preferably about 45 nM. 
Metoda kao u patentnom zahtjevu 1, gdje je spomenuta koncentracija MCSF u koraku c) preporučeno 50 nM, te još preporučenije 45 nM.
A pharmaceutical aerosol solution composition according to claim 12 wherein the overall formoterol degradation products level is lower than 2% w/w with respect to the theoretical formoterol fumarate content of 6µg/actuation and the residual level of the formoterol fumarate is higher than 95% w/w with respect to its initial content. 
Farmaceutski pripravak aerosolne otopine prema patentnom zahtjevu 12 u kojem je ukupna razina degradacijskog produkta formoterola niža od 2% w/w prema teorijskom sadržaju formoterol-fumarata od 6 ug/aktiviranju, a preostala razina formoterol-fumarata je viša od 95% w/w prema njegovom početnom sadržaju.
A pharmaceutical composition comprising a first and second pharmaceutically effective therapeutic agent, wherein the first agent is an antibody or antibody fusion protein as specified in claims 1 to 9 and the second agent is selected from the group consisting of: a chemotherapeutic agent, an angiogenesis inhibitor and an anti-tumor agent optionally together with a pharmaceutically acceptable carrier, diluent or excipient. 
Farmaceutski pripravak koji sadrži prvo i drugo farmaceutski učinkovito terapeutsko sredstvo, naznačen time da prvo sredstvo je protutijelo ili fuzijski protein protutijela kako je navedeno u zahtjevima 1 do 9, a drugo sredstvo je odabrano iz skupine koja sadrži: kemoterapijsko sredstvo, inhibitor angiogeneze i anti-tumorsko sredstvo proizvoljno zajedno sa farmaceutski prihvatljivim nosačem, otapalom ili pomoćnim sredstvom.
A cosmetic composition for lightening a skin and/or hair of a subject, the composition comprising a lignin peroxidase, a hydrogen peroxide-producing enzyme, and a substrate of said hydrogen peroxide-producing enzyme, wherein said hydrogen peroxide-producing enzyme comprises glucose oxidase and said substrate comprises D-glucose, and wherein a concentration of said glucose oxidase is in a range of from 1.25 to 125 units/gram and a concentration of said D-glucose is in a range of from 0.175 µmole/gram to 17.5 µmole/gram. 
Kozmetički sastav za posvjetljivanje kože i/ili kose subjekta, sastav sadržeći lignin peroksidazu, enzim koji proizvodi vodikov peroksid i supstrat navedenog enzima koji proizvodi vodikov peroksid, pri čemu navedeni enzim koji proizvodi vodikov peroksid sadrži glukoznu oksidazu, a navedeni supstrat sadrži D-glukozu, i pri čemu je koncentracija navedene glukozne oksidaze u rasponu od 1,25 do 125 jedinica/gram i koncentracija navedene D-glukoze je u rasponu od 0,175 µmol/gram do 17,5 µmola/gram.
Compound 9 was obtained from 3-aminothiophene and compound 3 by method D as a yellow solid (37 mg). 
Spoj 9 se dobiva iz 3-aminotiofena i spoja 3 pomoću postupka D kao žuta krutina (37 mg).
Bacterial strains Number of strains 
Broj međunarodne objave:
The non-magnetic transportation belt (2) runs at both ends over rotary wheels (pulleys) (12) one of them may at least be equipped with an electrical drive, the revolution of which may be controlled. Driving forces transmitted to the non-magnetic belt originate at least from an electrical drive. 
Uređaj u skladu s bilo kojim od prethodni patentnih zahtjeva 2 do 5, naznačen time što nemagnetnu transportnu vrpcu (2) navodi najmanje dva vodeća valjka (12), od kojih je jedan konfiguriran za prenošenje pogonskih sila od upravljivog električnog pogona na nemagnetnu transportnu vrpcu (2).
A method to permit a communication of at least one set of controlled credentials connected to a presenter from at least one server to a network endpoint, said method comprising the following steps performed by at least one server: 
Postupak koji omogućuje slanje najmanje jednog kompleta kontroliranih vjerodajnica povezano s prikazivačem iz najmanje jednog servera u krajnju točku mreže (110), naznačen time što se navedeni postupak sastoji u sljedećim koracima, koji se provode na najmanje jednom serveru:
The nitrile (AH) is reacted with an azide such as sodium azide, in the presence of a Lewis acid such as zinc bromide, to give the tetrazole of the structure (AI). 
Nitril (AH) reagira s azidom poput natrij azida, u prisutnosti Lewis kiseline poput cink bromida, da bi se dobio tetrazol strukture (AI).
The elastomer material of this invention may also incorporate other materials common in the field of manufacture of closures for pharmaceutical vials. 
Elastomerni materijal koji se koristi u ovom izumu može također uključivati druge uobičajene materijale iz područja proizvodnje zatvarača za farmaceutske bočice.
a light chain variable domain comprising: 
i ima slabi lanac (LC) koji obuhvaća:
The recombinant FVIII protein of claim 1, wherein the first half-life extending moiety is inserted immediately downstream of amino acid 40 of SEQ ID NO:1, corresponding to mature native human FVIII; and the second half-life extending moiety is inserted immediately downstream of amino acid 1656 of SEQ ID NO:1, corresponding to mature native human FVIII. The recombinant FVIII protein of claim 1, wherein the first half-life extending moiety is inserted immediately downstream of amino acid 1656 of SEQ ID NO:1, corresponding to mature native human FVIII; and the second half-life extending moiety is inserted immediately downstream of amino acid 1720 of SEQ ID NO:1, corresponding to mature native human FVIII. 
A2-1 regija odgovara regiji u nativnom zrelom humanom FVIII od oko aminokiseline 395 do oko aminokiseline 421 ili od oko aminokiseline 397 do oko aminokiseline 418 u SEQ ID NO:1, A2-2 regija odgovara regiji u nativnom zrelom humanom FVIII od oko aminokiseline 577 do oko aminokiseline 635 ili od oko aminokiseline 595 do oko aminokiseline 607 u SEQ ID NO:1, A3-1 regija odgovara regiji u nativnom zrelom humanom FVIII od oko aminokiseline 1705 do oko aminokiseline 1732 ili od oko aminokiseline 1711 do oko aminokiseline 1725 u SEQ ID NO:1; te
is a hydrogen atom, a C1-6 alkyl group optionally substituted by one or more halogen atoms, a cycloalkyl group, a cycloalkylcarbonyl group, a C1-6 alkanoyl group optionally substituted by one or more halogen atoms, a C2-6 alkenyl group, an amino substituted C1-6 alkanoyl group optionally substituted by one or more C1-6 alkyl groups, or a C1-6 alkylsulfonyl group: 
R" je atom vodika, C,4 alkil skupina opcijski supstituirana s jednim ili više halogen atoma, cikloalkil skupina, cikloalkilkarbonil skupina, C;4 alkanoil skupina opcijski supstituirana s jednim ili više halogen atoma, C24 alkenil skupina, amino supstituirana C;.4 alkanoil skupina opcijski supstituirana s jednom ili više C, 4 alkil skupina, ili Cig alkilsulfonil skupina;
ii) a second region (region B) which is covalently linked to the 5′ or 3′ nucleotide of the first region via a phosphodiester internucleoside linkage, wherein the second region consists of 2-10 phosphodiester linked DNA or RNA nucleosides; and 
(1) drugu regiju (regiju B) kovalentno vezanu na 5 ili 3 završetak nukleotida prve regije putem fosfodiesterske poveznice, pri čemu se regija B sastoji od barem dvije, poput najmanje tri uzastopne DNK i/ili RNK jedinice koje su vezane fosfodiesterskim poveznicama; 1
The method of claim 1, wherein the encoding information comprises at least one of the coded depth for the maximum coding unit, information about a partition type of a data unit for prediction encoding according to coding units corresponding to the coded depth, information about a prediction mode according to partitions of the coding units corresponding to the coded depth, and information about a size of a data unit for transformation according to the coding units corresponding to the coded depth. 
HR P20182053 T1 određivač jedinice za kodiranje (120) generira informaciju o veličini jedinice za transformaciju od jedinice kodiranja dubine kodiranja, pri čemu se dobiva barem jedna jedinica za transformaciju, prema veličini transformacijske jedinice, dijeljenjem visine i širine jedinice kodiranja trenutne dubine ili da podatkovna jedinica bude iste veličine kao jedinica kodiranja trenutne dubine 1 transformacija se izvršava na jedinici kodiranja trenutne dubine temeljeno na barem jednoj transformacijskoj jedinici.
Thus, the disclosure provides an antibody that binds to an epitope recognised by an antibody having the variable heavy chain sequence recited in SEQ ID NO: 86, and the variable light chain sequence recited in SEQ ID NO: 100. 
(b) varijabilno područje slabog lanca od sekvence SEQ ID NO: 86, i varijabilno područje jakog lanca od sekvence SEQ ID NO: 100;
Use, combination, composition, compound or product as claimed in claim 36, wherein the bacterial infection is an infection with Staphylococcus aureus or Streptococcus pneumoniae. 
Uporaba, kombinacije, pripravka, spoja ili produkta prema zahtjevu 36, naznačena time da bakterijska infekcija je infekcija bakterijom Staphilococcus aureus ili Streptococcus pneumoniae.
correlating the presence or absence of the immunological complex with the presence or absence of amyloid protein in the sample; and 
(d) koreliranja prisutnosti ili odsutnosti imunološkog kompleksa s prisutnošću ili odsutnošću amiloidnog proteina u uzorku; i
Further provided is a package comprising (b) an M3 antagonist of the invention and (a) a PDE4 inhibitor for the simultaneous, concurrent, separate or sequential use in the treatment of a said respiratory disease. 
Također je omogućena proizvodnja paketa koji sadrži (b) M3 antagonist sukladno predmetnom izumu i (a) B2 agonist za istovremenu, paralelnu, odvojenu ili sekvencijalnu uporabu u liječenju respiratorne bolesti koja odgovara na M3 antagonizam.
A prodrug of a compound of claim 1, or of the pharmaceutically acceptable salt of claim 2, wherein the prodrug is (i) an acetate, formate, or benzoate derivative of the phenolic hydroxy group, or (ii) an N-acyloxyalkyl pyridinium derivative. 
Prolijek spoja prema zahtjevu 1, ili farmaceutski prihvatljiva sol prema zahtjevu 2, pri čemu je prolijek (i) acetatni, formijatni ili benzoatni derivat fenolne hidroksilne skupine, ili (ii) N-aciloksialkil piridinij derivat.
This results in 1.15 g of a reaction crude that is purified by chromatography (Hx:AcOEt=3:2), which yields 0.65 g of the product of interest with a purity of 83%. 
Time se dobije 1,15 g sirovog proizvoda koji se očisti kromatografijom (Hx:AcOEt = 3:2) s iskorištenjem od 0,65 g željenog proizvoda čistoće 83%.
Use according to claim 13 wherein the immune disorder is an autoimmune disease. 
Uporaba prema zahtjevu 11 naznačena time da imunološki poremećaj je autoimuna bolest.
The method of any preceding claim wherein said step of providing (106, 208, 804) one or more service options to said requester comprise providing advertising to said requester. 
Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da spomenuti korak pribavljanja (106, 208, 804) jedne ili više uslužnih opcija za spomenutog podnositelja zahtjeva, obuhvaća pripremu oglašavanja navedenog podnositelja zahtjeva.
The soft chewable veterinary composition of claim 5, wherein the binder is polyvinylpyrrolidone or a polyethylene glycol, or a combination thereof. 
Mekani veterinarski pripravak za žvakanje prema zahtjevu 5, naznačen time, da vezivo je polivinilpirolidon, ili polietilen-glikol, ili njihove kombinacije.
The pooling device of embodiment 18, wherein said fluid connection assembly [104] includes a unidirectional check valve [186] being connected to said inlet port of said pooling device for selectively regulating a directional fluid flow of the fluid. 
Uređaj za objedinjavanje prema zahtjevu 6, naznačen time što navedeni sklop za spajanje fluida [104] sadrži jednosmjerni nepovratni ventil [186] koji je spojen na navedeni ulazni otvor navedenog uređaja za objedinjavanje radi selektivnog reguliranja usmjerenog fluidnog strujanja fluida.